NCT06904287

Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines

Evaluating the Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines in the Emergency Department

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.

Detailed description

The purpose of this prospective, randomized, double-blinded study is to compare the relative efficacy and safety of intravenous magnesium in conjunction with intravenous prochlorperazine in the treatment of migraines. Participants will be patients presenting to the Emergency Department with primary diagnosis of migraine.

Conditions

• Migraine

Interventions

Type	Name	Description
DRUG	Magnesium	Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by magnesium 2 g administered as an intravenous bolus over a period of 20 minutes
DRUG	Placebo	Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by placebo (normal saline)

Timeline

• Start date: 2025-12-16
• Primary completion: 2027-06-01
• Completion: 2027-06-01
• First posted: 2025-04-01
• Last updated: 2026-01-22

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study